Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
adjuvant, atezolizumab, bevacizumab, chondrosarcoma, dialog, draft, epithelioid, IND, leiomyosarcoma, LPI, month, osteosarcoma, pack, pool, prepay, pro, promptly, rata, recurrent, respond, responding, Roche, shifted, sixty, SOC, soft, tissue, unamortized, Vec, written
Removed:
clearance, endpoint, entry, NSCLC, released
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view